Dexcom receives FDA clearance for G7 15 Day glucose monitoring system

The article discusses the FDA clearance of Dexcom’s G7 15 Day continuous glucose monitoring system for individuals with type 1, type 2, and gestational diabetes. Here are three highlights from the article:

1. The G7 15 Day system, set to launch in the second half of the year, offers a longer wear time of 15.5 days (including a 12-hour grace period) and sends real-time glucose information to the Dexcom G7 app or receiver every five minutes without the need for fingersticks or scanning.

2. The system boasts an overall mean absolute relative difference (MARD) of 8.0%, a key parameter to assess the measurement performance of CGM systems, according to the National Library of Medicine.

Editorial content by NewsSIP AI